Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Eagle’s Eye View: New ACC/AHA Dyslipidemia Guidelines ReleasedIn this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life.
- CathPCI Registry Findings: PCI For Stent Thrombosis, AKI Risk and SDD, MoreRecent studies informed by data from ACC's CathPCI Registry explore trends in PCI for stent thrombosis; contrast media dosing during PCI; acute kidney injury (AKI) and same-day discharge (SDD); and disparities in use of atherectomy and intravascular lithotripsy (IVL) during PCI.
- ACCEL Lite: Cardiovascular-Kidney Therapies in CKDIn this interview, Allen J. Taylor, MD, FACC and Janani Rangaswami, MD examine “Cardiovascular-Kidney Therapies in CKDâ€.
- Pre-Hospital Glycoprotein IIb/IIIa Inhibition With Zalunfiban in STEMIThe CELEBRATE (CeleCor Blinded Randomized Trial in ST-Elevation Myocardial Infarction) trial was a phase 3, multicenter, double-blind, placebo-controlled study that evaluated the efficacy and safety of a single subcutaneous injection of zalunfiban (CeleCor Therapeutics), a novel glycoprotein IIb/IIIa inhibitor...
- ACC, AHA Release New Clinical Guideline For Managing DyslipidemiaThe new ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop†for addressing the evaluation, management and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]).